🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 60855D101
- Market Cap
- Micro Cap
- IPO
- 6/2/2016 · $6.00/share
Business: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers. The Company's clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. They are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.
Company Contact
- CHR
- Walter Klemp
- CFO
- Jonathan P. Foster
- Headquarters
- 5300 Memorial Drive, Suite 950, Houston, TX 77007
- Phone
- 713-300-5160
- Investor Relations
- Jenene Thomas, JTC Team · 833-475-8247 · MBRX@jtcir.com